Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions (NYSE: EBS) has announced its participation in several upcoming investor conferences. Notable events include the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, with a fireside chat at 1:30 PM ET, and the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:00 PM ET. Additionally, Emergent will attend the Goldman Sachs 7th Annual Leveraged Finance and Credit Conference from May 11 to 13, 2022, with further details to be provided on their website. Webcasts will be available for live viewing and replay.
- None.
- None.
GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences:
- KeyBanc Life Sciences & MedTech Investor Forum
March 22, 2022
Company fireside chat scheduled for 1:30 pm eastern
https://wsw.com/webcast/key21/ebs/1521976
- BofA Securities 2022 Healthcare Conference
May 10, 2022
Presentation scheduled for 12:00 pm eastern
- Goldman Sachs 7th Annual Leveraged Finance and Credit Conference
May 11 to 13, 2022
Presentation date and time will be updated on the Emergent website as the information becomes available.
For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 20 years, we’ve been at work defending people from things we hope will never happen—so we are prepared, just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com
Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com
FAQ
What events will Emergent BioSolutions (EBS) attend in March 2022?
When is the BofA Securities 2022 Healthcare Conference for Emergent BioSolutions (EBS)?
What is the date for the Goldman Sachs 7th Annual Leveraged Finance and Credit Conference for EBS?
Will Emergent BioSolutions (EBS) provide webcasts for their presentations?